ENVB
Income statement / Annual
Last year (2023), Enveric Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Enveric Biosciences, Inc.'s net income was -$17,291.73.
See Enveric Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$39.91 M
|
$43.00 M
|
$48.59 M
|
$36.15 M
|
$15.98 M
|
$0.00
|
| Cost of Revenue |
$408,030.00 |
$435,201.00 |
$681,612.00 |
$120,872.00 |
$31.76 M |
$34.01 M |
$38.36 M |
$29.61 M |
$10.23 M |
$0.00 |
| Gross Profit |
-$408,030.00 |
-$435,201.00 |
-$681,612.00 |
-$120,872.00 |
$8.15 M |
$8.98 M |
$10.24 M |
$6.54 M |
$5.75 M |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0.2 |
0.21 |
0.21 |
0.18 |
0.36 |
0 |
| Research and Development
Expenses |
$7.25 M
|
$8.03 M
|
$4.79 M
|
$174,083.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$8.85 M
|
$11.61 M
|
$20.50 M
|
$5.44 M
|
$2,296.53
|
$0.00
|
$0.00
|
$8.55 M
|
$5.69 M
|
$32,811.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.21 M
|
$0.00
|
$0.00
|
$417,249.00
|
$119,847.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.85 M
|
$11.61 M
|
$20.50 M
|
$5.44 M
|
$12.21 M
|
$10.79 M
|
$18.51 M
|
$8.97 M
|
$5.81 M
|
$32,811.00
|
| Other Expenses |
$343,982.00 |
$327,910.00 |
$656,643.00 |
-$802,109.00 |
$2.27 M |
$88,161.00 |
$1.08 M |
-$394,213.00 |
$157,941.00 |
$0.00 |
| Operating Expenses |
$16.45 M |
$19.96 M |
$25.94 M |
$5.62 M |
$14.48 M |
$13.70 M |
$21.73 M |
$10.33 M |
$5.97 M |
$32,811.00 |
| Cost And Expenses |
$16.45 M |
$19.96 M |
$25.94 M |
$5.62 M |
$46.24 M |
$47.71 M |
$60.08 M |
$39.94 M |
$16.19 M |
$32,811.00 |
| Interest Income |
$0.00 |
$5.25 |
$10.32 |
$445.25 |
$81.82 |
$0.00 |
$0.00 |
$0.00 |
$89,918.00 |
$0.00 |
| Interest Expense |
$3,708.00 |
$5,249.00 |
$10,316.00 |
$445,250.00 |
$691,138.00 |
$729,896.00 |
$575,039.00 |
$751,074.00 |
$238,471.00 |
$0.00 |
| Depreciation &
Amortization |
$343.98
|
$435,201.00
|
$681,612.00
|
$120,872.00
|
$2.27 M
|
$2.90 M
|
$3.22 M
|
$1.36 M
|
$157,941.00
|
$0.00
|
| EBITDA |
-$17.14 M
|
-$19.63 M
|
-$63.97 M
|
-$6.30 M
|
-$2.33 M
|
-$6.92 M
|
-$7.67 M
|
-$4.41 M
|
-$537,780.00
|
-$32,811.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
-0.1 |
-0.04 |
-0.15 |
-0.08 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
-0.16
|
-0.17
|
-0.25
|
-0.15
|
-0.12
|
0
|
| Total Other
Income/Expenses Net |
-$814,379.00
|
$7.46 M
|
$8.19 M
|
-$1.25 M
|
-$2.41 M
|
-$10.55 M
|
-$11.47 M
|
-$2.73 M
|
-$1.23 M
|
$0.00
|
| Income Before Tax |
-$17.26 M |
-$19.96 M |
-$56.43 M |
-$6.86 M |
-$5.22 M |
-$10.55 M |
-$11.47 M |
-$6.53 M |
-$2.02 M |
-$32,811.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
-0.13
|
-0.25
|
-0.24
|
-0.18
|
-0.13
|
0
|
| Income Tax Expense |
$28,913.00 |
-$1.49 M |
-$7.45 M |
-$477,731.00 |
$388,657.00 |
$6.35 M |
-$2.39 M |
-$3.75 M |
-$128,460.00 |
$833.00 |
| Net Income |
-$17,291.73 |
-$18.47 M |
-$48.98 M |
-$6.39 M |
-$5.60 M |
-$16.90 M |
-$9.07 M |
-$2.78 M |
-$1.89 M |
-$33,644.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
-0.14 |
-0.39 |
-0.19 |
-0.08 |
-0.12 |
0 |
| EPS |
-8.09 |
-12.77 |
-103.69 |
-55.5 |
-211.99 |
-3551.39 |
-3028.98 |
-1064.17 |
-856.06 |
-192.25 |
| EPS Diluted |
-8.09 |
-12.77 |
-103.69 |
-55.5 |
-211.99 |
-3551.39 |
-3028.98 |
-1064.17 |
-851.69 |
-192.25 |
| Weighted Average Shares
Out |
$2.16 M
|
$1.45 M
|
$472,342.00
|
$115,071.00
|
$26,435.00
|
$4,758.00
|
$2,996.00
|
$2,613.00
|
$2,374.00
|
$1,325.00
|
| Weighted Average Shares
Out Diluted |
$2.16 M
|
$1.45 M
|
$472,342.00
|
$115,071.00
|
$26,435.00
|
$4,758.00
|
$2,996.00
|
$2,613.00
|
$2,220.00
|
$1,325.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
